218 related articles for article (PubMed ID: 22094905)
1. Dysregulated expression of both the costimulatory CD28 and inhibitory CTLA-4 molecules in PB T cells of advanced cervical cancer patients suggests systemic immunosuppression related to disease progression.
Kosmaczewska A; Bocko D; Ciszak L; Wlodarska-Polinska I; Kornafel J; Szteblich A; Masternak A; Frydecka I
Pathol Oncol Res; 2012 Apr; 18(2):479-89. PubMed ID: 22094905
[TBL] [Abstract][Full Text] [Related]
2. The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.
Karpathiou G; Chauleur C; Mobarki M; Peoc'h M
Pathol Res Pract; 2020 Jan; 216(1):152782. PubMed ID: 31862202
[TBL] [Abstract][Full Text] [Related]
3. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
4. Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia.
Frydecka I; Kosmaczewska A; Bocko D; Ciszak L; Wolowiec D; Kuliczkowski K; Kochanowska I
Br J Cancer; 2004 May; 90(10):2042-8. PubMed ID: 15138491
[TBL] [Abstract][Full Text] [Related]
5. A transendocytosis perspective on the CD28/CTLA-4 pathway.
Soskic B; Qureshi OS; Hou T; Sansom DM
Adv Immunol; 2014; 124():95-136. PubMed ID: 25175774
[TBL] [Abstract][Full Text] [Related]
6. Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.
Karabon L; Partyka A; Ciszak L; Pawlak-Adamska E; Tomkiewicz A; Bojarska-Junak A; Roliński J; Wołowiec D; Wrobel T; Frydecka I; Kosmaczewska A
J Immunol Res; 2020; 2020():6545921. PubMed ID: 32775467
[TBL] [Abstract][Full Text] [Related]
7. [Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].
Chi PD; Li L; Fan YY; Wu CY
Ai Zheng; 2007 Aug; 26(8):801-8. PubMed ID: 17697537
[TBL] [Abstract][Full Text] [Related]
8. K12/SECTM1, an interferon-γ regulated molecule, synergizes with CD28 to costimulate human T cell proliferation.
Wang T; Huang C; Lopez-Coral A; Slentz-Kesler KA; Xiao M; Wherry EJ; Kaufman RE
J Leukoc Biol; 2012 Mar; 91(3):449-59. PubMed ID: 22184754
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of Cytotoxic T-Lymphocyte-Associated Antigen-4 Prevents Atherosclerosis in Mice.
Matsumoto T; Sasaki N; Yamashita T; Emoto T; Kasahara K; Mizoguchi T; Hayashi T; Yodoi K; Kitano N; Saito T; Yamaguchi T; Hirata K
Arterioscler Thromb Vasc Biol; 2016 Jun; 36(6):1141-51. PubMed ID: 27055906
[TBL] [Abstract][Full Text] [Related]
10. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production.
Freeman GJ; Lombard DB; Gimmi CD; Brod SA; Lee K; Laning JC; Hafler DA; Dorf ME; Gray GS; Reiser H
J Immunol; 1992 Dec; 149(12):3795-801. PubMed ID: 1281186
[TBL] [Abstract][Full Text] [Related]
11. Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation.
Dengler TJ; Szabo G; Sido B; Nottmeyer W; Zimmerman R; Vahl CF; Hünig T; Meuer SC
Transplantation; 1999 Feb; 67(3):392-8. PubMed ID: 10030284
[TBL] [Abstract][Full Text] [Related]
12. Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.
Lazetic S; Leong SR; Chang JC; Ong R; Dawes G; Punnonen J
J Biol Chem; 2002 Oct; 277(41):38660-8. PubMed ID: 12167647
[TBL] [Abstract][Full Text] [Related]
13. CD40L, CD28, and CTLA-4 expression on CD4+ T cells in kidney graft recipients: a relationship with post-transplantation clinical course.
Kosmaczewska A; Magott-Procelewska M; Frydecka I; Ciszak L; Bocko D; Szteblich A; Kusnierczyk P; Patrzalek D; Szyber P; Klinger M
Transpl Immunol; 2006 Jun; 16(1):32-40. PubMed ID: 16701174
[TBL] [Abstract][Full Text] [Related]
14. Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population.
Pawlak E; Karabon L; Wlodarska-Polinska I; Jedynak A; Jonkisz A; Tomkiewicz A; Kornafel J; Stepien M; Ignatowicz A; Lebioda A; Dobosz T; Frydecka I
Hum Immunol; 2010 Feb; 71(2):195-200. PubMed ID: 19913589
[TBL] [Abstract][Full Text] [Related]
15. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development.
Ewing MM; Karper JC; Abdul S; de Jong RC; Peters HA; de Vries MR; Redeker A; Kuiper J; Toes RE; Arens R; Jukema JW; Quax PH
Int J Cardiol; 2013 Oct; 168(3):1965-74. PubMed ID: 23351788
[TBL] [Abstract][Full Text] [Related]
16. Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells.
Moosig F; Csernok E; Wang G; Gross WL
Clin Exp Immunol; 1998 Oct; 114(1):113-8. PubMed ID: 9764612
[TBL] [Abstract][Full Text] [Related]
17. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.
Wang X; Wang T; Xu M; Xiao L; Luo Y; Huang W; Zhang Y; Geng W
Hum Immunol; 2014 Dec; 75(12):1203-9. PubMed ID: 25446402
[TBL] [Abstract][Full Text] [Related]
18. Differences in allergen-induced T cell activation between allergic asthma and rhinitis: Role of CD28, ICOS and CTLA-4.
Botturi K; Lacoeuille Y; Cavaillès A; Vervloet D; Magnan A
Respir Res; 2011 Feb; 12(1):25. PubMed ID: 21356099
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of alternate co-stimulatory molecules on proinflammatory CD28null T cells in bronchiolitis obliterans syndrome.
Hodge G; Hodge S; Ahern J; Holmes-Liew CL; Reynolds PN; Holmes M
Clin Exp Immunol; 2013 Jul; 173(1):150-60. PubMed ID: 23607447
[TBL] [Abstract][Full Text] [Related]
20. Rapid turnover of the CD8(+)CD28(-) T-cell subset of effector cells in the circulation of patients with head and neck cancer.
Tsukishiro T; Donnenberg AD; Whiteside TL
Cancer Immunol Immunother; 2003 Oct; 52(10):599-607. PubMed ID: 12827303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
